Lonza Group AG got downgraded by Zacks Investment Research from the ‘hold’ to ‘sell’ rating

On Friday, Zack Investment Research downgraded LONZA GRP AG/ADR from the ‘’hold” rating to a “sell” rating.

According to Zacks, Lonza Group AG works as a supplier to the life science, healthcare, and pharma industries. The activities of the firm are divided into 4 categories: Bioscience, Microbial Control, Life Science Ingredients, & Custom Manufacturing. The Bioscience division includes bioscience products, inclusive of cell culture & molecular biology tools for tests or research for detection of microbes and media employed in the production of therapeutics. The focus of the Microbial Control division is on the following area: water treatment, industrial preservation, hygiene, wood protection, and oil/gas applications and includes products covering sterilizers to household cleaning products. The company’s Life Science Ingredients segment covers nutrition ingredients for applications in nutrition (food, feed and pharma application) and chemical intermediates for the industry of agriculture. The Custom Manufacturing division includes products which are used in the pharma sector.

Headquarter of the Lonza Group AG is based in Switzerland.

The opening stock of the LONZA GRP AG was $33.68. The moving average of the 50th day of the company is $32.10. The firm has a 12 month high of $34.79& a 12 month low of $24.70. The market capital of stock is of $25.08 billion.

Lonza Group Limited supplies products, as well as, services to the biotech, pharma, and specialty ingredients markets all across the world. The firm operates in two segments, Specialty, and Biotech&Pharma ingredients. The services and products of the firm cover solutions for bioresearch, inclusive of Cell culture, exosomes & assay solutions, stem cells primary cells & media, primary & stem cell protocols, Hepatocytes solutions for microsomes & primary cell culture applications, and CytoSMART system where there is a live cell imaging & monitoring system.